Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Charles River Laboratories Enters Strategic Partnership with AstraZeneca

Published: Friday, October 19, 2012
Last Updated: Friday, October 19, 2012
Bookmark and Share
Global CRO partners with global biopharmaceutical company to accelerate drug development.

Charles River Laboratories International, Inc. announced that it has been selected by AstraZeneca as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

James C. Foster, Chairman, President and Chief Executive Officer of Charles River said, “We are extremely pleased that AstraZeneca selected Charles River as its strategic in vivo biology partner. Utilizing our capabilities will enable AstraZeneca to create a flexible research platform to deliver innovative health solutions. Our shared passion for scientific excellence is a strong foundation for this relationship, and we look forward to working with AstraZeneca’s scientists ‘on the same side of the table’ to achieve their drug development goals.”

Stefan Platz, Vice President, Global Safety Assessment, AstraZeneca said, “Tapping into the high quality drug development services of a trusted strategic partner enables AstraZeneca to increase our resource flexibility while simplifying the way we work. We are pleased to partner with Charles River to utilize their scientific expertise, such as their customized in vivo biology program. Our organisations will work hand-in-hand to deliver toxicology, safety pharmacology and development DMPK studies in support of our efforts to deliver safe and effective new treatments to patients more efficiently.”

The three-year agreement extends into 2015. AstraZeneca began the process of transferring programs to Charles River earlier this year. This process is expected to be completed by early 2013. In 2013, the incremental sales under this agreement are expected to contribute approximately 1% to Charles River’s total net sales.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Charles River Laboratories to Acquire Celsis International
Enhances Charles River Endotoxin and Microbial Detection’s position as the most comprehensive solution for rapid quality control testing.
Thursday, July 16, 2015
Charles River Acquires ChanTest
Addition broadens Charles Rivers' existing discovery-focused ion channel capabilities.
Friday, October 31, 2014
Charles River Laboratories Completes Acquisition of Galapagos’ CRO Services
Acquisition is expected to add approximately 6% to Company’s net sales in 2014.
Thursday, April 03, 2014
Charles River to Acquire Argenta and BioFocus from Galapagos
Capabilities of companies' more than 340 scientists will augment Charles River’s position.
Thursday, March 13, 2014
Charles River Laboratories Announces First-Quarter 2013 Results from Continuing Operations
First-quarter sales of $291.2 million.
Thursday, May 02, 2013
Charles River Laboratories Completes Acquisition of Majority Ownership of Vital River
Charles River Laboratories International, Inc. takes 75% ownership of Vital River, the premier commercial provider of research models and related services in China, and a licensee of Charles River for the last ten years.
Tuesday, January 08, 2013
Charles River Announces Second-Quarter 2012 Results from Continuing Operations
Second-quarter sales of $284.7 million.
Thursday, August 09, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!